Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of BI 1015550 formulations in healthy subjects
NCT06408870Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nerandomilast (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 144 hours and Maximum Measured Concentration of Nerandomilast in Plasma at 144 hours. Started Jun 2024; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT06408870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06408870.